CD123

CD123

a type I transmembrane protein present on pluripotent stem cells and committed hemopoietic progenitor cells that is involved in cell proliferation and/or differentiation.
References in periodicals archive ?
57) Hairy cell leukemia is positive for all common B-cell antigens (CD19, CD20, CD79a, FMC-7, and PAX5), with characteristic expression of annexin A1 (Figure 7, A), CD11c, CD25, CD103, CD123, DBA-44 (CD72) (Figure 7, B), the Hector Battifora mesothelial epitope-1 (HBME-1), pERK, Tbet, and TRAP58-61 but is typically negative for CD5 and CD10, although 10% to 20% of HCLs are positive for CD10.
Plasmacytoid CD123 (PCD) dendritic cells have tolerogenic effects, and they gradually increase in number during the rejection-free post-transplant period.
CD123, the plasmacytoid dendritic cell phenotypic marker is abundant in leprosy type 1 reaction.
For example, human pDC characteristically express high levels of IL-3 receptor alpha chain (CD123), but in the mouse, pDC do not normally express CD123.
The product is a humanised, Dual-Affinity Re-Targeting bi-specific antibody-based molecule that binds to both CD123 and CD3, antigens expressed on leukemic cells and T lymphocytes, respectively.
In addition, markers recently developed for PDCs, including CD123 (the interleukin-3 receptor), blood dendritic cell antigen 2 (BDCA2/CD303), (5) and T-cell leukemia/lymphoma 1 (TCL1) and CD2-associated protein (CD2AP), (6) were rarely tested in the literature published prior to 2008.
T cells were magnetically labelled by a cocktail of biotin-conjugated antibodies against CD8, CD14, CD15, CD16, CD19, CD25, CD34, CD36, CD45RO, CD56, CD123, TCR[gamma]/[delta], HLA-DR, CD235a (Glycophorine A) and anti-biotin micro-beads.
En la tabla 10 se presenta el analisis de intensidad media de fluorescencia de los marcadores HLA-DR, CD45 y CD123 en las celulas dendriticas plasmacitoides, en las que se observan niveles elevados de expresion de HLA-DR y CD123 caracteristicos de estas celulas (Figura 6), (6).
The promising drug is an antibody that blocks a receptor called CD123 found on the surface of stem cells at risk of developing into leukemia cells.
The new treatment targets a protein, CD123, on the surface of cancer stem cells that drive acute myeloid leukemia (AML), which is an aggressive disease with a poor outcome.
Investigation of the normal differentiation pathways of CD34+ precursors as regards the acquisition of MPO, lysozyme, CD64, CD15, or CD123 expression will certainly contribute to a better discrimination among the different myeloid cell lineages (120-122,124,125).